Lundbeck Q3 2019 Financial Results

Lu AG06466 in phase lb study in neuropathic pain Neuropathic pain (NP) Ongoing phase I study1: 36 MGLLI have shown to reduce pain in preclinical models of inflammatory, post-surgical, and neuropathic pain Significant scientific evidence supports the use of exocannabinoids for the treatment of pain, including controlled clinical studies in patients with NP MGLLI may offer significant therapeutic benefits over exocannabinoids, with potential for increased NP results from damage to the nervous system in the brain or spinal cord or in the peripheral nerves * * * NP is a common and debilitating condition that may occur in 10% of Americans * * Current approved treatments for NP include gabapentinoids and antidepressants * Beyond the lack of effective medications, many patients chronically use opioid drugs * efficacy and a better safety profile Designed to identify a titration regimen of Lu AG06466 ~38 adult patients with peripheral neuropathic pain The efficacy of Lu AG06466 in treating neuropathic pain will be assessed by the change from baseline in pain intensity scores using numerical rating scale (NRS-11) Study initiated in Q4 2017 There is a pressing need for efficacious non-opioid therapies for NP 1) NCT03447756. This study will enrol patients with peripheral neuropathic pain due to one of the four following diagnostic groups: post-herpetic neuralgia, diabetic peripheral neuropathy, small fiber neuropathy or post-traumatic neuropathic pain 1) Lundbeck

View entire presentation